Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 186 of 186 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02321501	Phase I	Ceritinib + Everolimus	Ceritinib and Everolimus in Treating Patients with Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT02465060	Phase II	Erdafitinib Trametinib Crizotinib Sapanisertib Fexagratinib Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Active, not recruiting	USA	2
NCT02568267	Phase II	Entrectinib	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	USA \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	6
NCT02696993	Phase Ib/II	Nivolumab Ipilimumab + Nivolumab	Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03334617	Phase II	Danvatirsen + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab	Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)	Active, not recruiting	USA \| ISR \| FRA \| ESP \| DEU \| CAN \| AUT	1
NCT03469960	Phase III	Ipilimumab + Nivolumab	Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (DICIPLE)	Active, not recruiting	FRA	0
NCT03516981	Phase II	MK-1308 + Pembrolizumab MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab	A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)	Active, not recruiting	USA \| POL \| ITA \| IRL \| GBR \| ESP \| CHE \| CAN \| AUS	7
NCT03559049	Phase Ib/II	Carboplatin + Pembrolizumab + Pemetrexed Disodium + Rucaparib	Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03793179	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium	Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer	Active, not recruiting	USA \| CAN	1
NCT03915951	Phase II	Binimetinib + Encorafenib	An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer	Active, not recruiting	USA \| NLD \| ITA \| ESP	1
NCT03977194	Phase III	Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel	Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY)	Active, not recruiting	FRA	0
NCT03993873	Phase Ib/II	Elzovantinib	Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1)	Active, not recruiting	USA \| FRA \| ESP	2
NCT04033354	Phase III	Carboplatin + Nab-paclitaxel + Serplulimab Carboplatin + Nab-paclitaxel	A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC	Active, not recruiting	USA \| TUR \| POL	4
NCT04108026	Phase II	Durvalumab	Immunotherapy in Patient with Poor General Condition (SAVIMMUNE)	Active, not recruiting	FRA	0
NCT04140500	Phase I	RO7247669	Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors	Active, not recruiting	TUR \| ISR \| GBR \| ESP \| DNK	4
NCT04223596	Phase II	Brigatinib	Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK)	Active, not recruiting	ESP	0
NCT04526782	Phase II	Docetaxel Binimetinib + Encorafenib	ENCOrafenib with Binimetinib in BRAF NSCLC (ENCO-BRAF)	Active, not recruiting	FRA	0
NCT04547504	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium	PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 >= 50 % (PERSEE)	Active, not recruiting	FRA	0
NCT04621188	Phase II	Lorlatinib	Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)	Active, not recruiting	FRA	0
NCT04623775	Phase II	Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab	A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Active, not recruiting	USA \| ROU \| POL \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	3
NCT04655976	Phase II	Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly Docetaxel + Dostarlimab-gxly	Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy (COSTAR Lung)	Active, not recruiting	USA \| TUR \| SWE \| ROU \| POL \| NLD \| ITA \| GRC \| GBR \| FRA \| FIN \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG	6
NCT04738487	Phase III	Pembrolizumab MK-7684A	Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)	Active, not recruiting	USA \| TUR \| ROU \| HUN \| CAN \| BRA	17
NCT04746924	Phase III	Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab	A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| FRA \| ESP \| DEU \| BRA \| AUS \| ARG	8
NCT04776447	Phase II	Atezolizumab + Carboplatin + Paclitaxel	Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO)	Active, not recruiting	ESP	0
NCT04956692	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab	Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)	Active, not recruiting	USA \| TUR \| ROU \| POL \| HUN \| FRA \| ESP \| BRA	8
NCT04984811	Phase II	Atezolizumab + NT-I7	NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC	Active, not recruiting	USA	0
NCT05000710	Phase II	Durvalumab Durvalumab + Tremelimumab Tremelimumab	Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung)	Active, not recruiting	ISR	0
NCT05012254	Phase II	Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium	Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain)	Active, not recruiting	ESP	0
NCT05144997	FDA approved	Lorlatinib	Lorlatinib Continuation Study	Active, not recruiting	USA \| FRA \| ESP	5
NCT05635708	Phase II	Nab-paclitaxel Cisplatin BGB-15025 + Tislelizumab BGB-A445 + Tislelizumab Paclitaxel Tislelizumab Carboplatin Pemetrexed Disodium LBL-007 + Tislelizumab	A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer	Active, not recruiting	USA \| ROU \| ITA \| FRA \| ESP \| CAN \| BRA \| AUS	7
NCT05687266	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Durvalumab Cisplatin + Pembrolizumab + Pemetrexed Disodium	Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)	Active, not recruiting	USA \| TUR \| SWE \| POL \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BGR \| AUT	8
NCT05746481	Phase II	Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab	Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases	Active, not recruiting	USA	0
NCT05781308	Phase II	Atezolizumab + Bevacizumab + Paclitaxel Bevacizumab + Paclitaxel	Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE)	Active, not recruiting	FRA	0
NCT06099782	Phase II	MK-3475A Pembrolizumab	A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)	Active, not recruiting	USA \| TUR \| POL \| NZL \| FRA \| AUS \| ARG	3
NCT06532032	Phase Ib/II	Amivantamab-vmjw + Docetaxel	A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (swalloWTail)	Active, not recruiting	USA \| TUR \| GBR	1
NCT06797362	Expanded access	NUV-520	Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC (NVL-520-EAP)	Available	USA \| NLD \| GBR \| FRA \| CAN \| AUS	1
NCT00585195	Phase I	Crizotinib + Itraconazole Crizotinib + Rifampin	A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)	Completed	USA \| AUS	2
NCT01970865	Phase II	Lorlatinib Crizotinib	A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations	Completed	USA \| ITA \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL \| AUS	5
NCT02279433	Phase I	Taletrectinib	A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	Completed	USA	0
NCT02879617	Phase II	Durvalumab	A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients	Completed	USA	0
NCT03088930	Phase II	Crizotinib	Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer	Completed	USA	0
NCT03308942	Phase II	Niraparib Niraparib + Pembrolizumab Dostarlimab-gxly + Niraparib	Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants	Completed	USA	0
NCT03322540	Phase II	Pembrolizumab Epacadostat + Pembrolizumab	Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)	Completed	USA \| TUR \| POL \| ITA \| ISR \| IRL \| GBR \| EST \| ESP \| DNK \| CHE \| CAN \| AUS	5
NCT03322566	Phase II	Carboplatin + Paclitaxel + Pembrolizumab Epacadostat + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab Cisplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium	A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)	Completed	USA \| TUR \| ITA \| ISR \| IRL \| HUN \| GBR \| ESP \| CAN \| AUS	4
NCT03468985	Phase II	Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab	Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer	Completed	USA	0
NCT03591731	Phase II	Nivolumab Ipilimumab + Nivolumab	Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC)	Completed	FRA	0
NCT03631706	Phase II	Bintrafusp alfa Pembrolizumab	M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| TUR \| NLD \| ITA \| GRC \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| ARG	6
NCT03664024	Phase II	Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium	Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782)	Completed	USA \| ISR \| HUN \| ESP \| CAN	0
NCT03708328	Phase I	RO7121661	A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors	Completed	USA \| NZL \| FRA \| ESP \| DNK	1
NCT03829319	Phase III	Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium	Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)	Completed	USA \| TUR \| POL \| NZL \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS \| ARG	5
NCT03840915	Phase Ib/II	Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Bintrafusp alfa + Docetaxel Bintrafusp alfa + Carboplatin + Pemetrexed Disodium Bintrafusp alfa + Cisplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Nab-paclitaxel	M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| FRA \| BEL	0
NCT04263051	Phase II	Nivolumab + UCPVax	Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer (Optim-UCPVax)	Completed	FRA	0
NCT04725188	Phase II	Docetaxel Docetaxel + MK-7684A MK-7684A	Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)	Completed	USA \| POL \| ITA \| ISR \| FRA \| FIN \| ESP \| DNK \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	5
NCT04793815	FDA approved	Pembrolizumab	Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)	Completed	CAN	0
NCT04832854	Phase II	Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab Atezolizumab + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Gemcitabine + Tiragolumab Atezolizumab + Cisplatin + Gemcitabine + Tiragolumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium	A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer	Completed	USA \| ESP \| CHE \| AUS	1
NCT05005273	Phase II	Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab	A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer	Completed	USA \| TUR \| POL \| ITA \| ISR \| FRA \| ESP \| DEU \| BEL \| AUS \| ARG	1
NCT02473497	Expanded access	Crizotinib	Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients	No longer available	USA	0
NCT06364917	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab	DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC	Not yet recruiting	USA	0
NCT06656598	Phase II	Carboplatin + Cemiplimab + Paclitaxel	Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Stage III Lung Cancer (SPORADIC)	Not yet recruiting	FRA	0
NCT06680050	Phase II	Ceralasertib + Durvalumab	Phase II Study of Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen (AUSTRAL) (AUSTRAL)	Not yet recruiting	ITA \| CHE	0
NCT06743581	Phase Ib/II	Cemiplimab Dupilumab	Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer (Dupi-Cemi)	Not yet recruiting	CAN	0
NCT06917573	Phase II	Cemiplimab Carboplatin + Cemiplimab + Paclitaxel	PALACE: Cemiplimab Trial According to ctDNA Levels (PALACE)	Not yet recruiting	ESP	0
NCT06937905	Phase III	Tarlatamab	Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) (TARLANEC)	Not yet recruiting	FRA	0
NCT06946797	Phase II	Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Ipilimumab + Nivolumab	A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (CheckMate-1533)	Not yet recruiting	USA \| TUR \| ROU \| POL \| ITA \| GRC \| FRA \| BRA	3
NCT03093116	Phase Ib/II	Repotrectinib	A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Recruiting	USA \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL \| AUS	6
NCT03175224	Phase Ib/II	Vebreltinib	APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)	Recruiting	USA \| ITA \| HUN \| GBR \| FRA \| FIN \| ESP \| CAN \| AUS	4
NCT03475953	Phase Ib/II	Avelumab + Regorafenib	A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)	Recruiting	FRA	0
NCT03786692	Phase II	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Pemetrexed Disodium Bevacizumab + Carboplatin + Pemetrexed Disodium	Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC	Recruiting	USA	0
NCT03965468	Phase II	Carboplatin + Durvalumab + Paclitaxel + Tremelimumab	Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS)	Recruiting	NLD \| ITA \| ESP \| CHE	0
NCT03994796	Phase II	Adagrasib Abemaciclib GDC-0084 Entrectinib	Genetic Testing in Guiding Treatment for Patients With Brain Metastases	Recruiting	USA	0
NCT04084717	Phase II	Crizotinib	Study of Crizotinib for ROS1 and MET Activated Lung Cancer	Recruiting	CAN	0
NCT04105270	Phase II	Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium	RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial	Recruiting	USA	0
NCT04116541	Phase II	Alectinib Regorafenib Dabrafenib + Trametinib Cabozantinib Avapritinib	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors. (MegaMOST)	Recruiting	FRA	0
NCT04270591	Phase Ib/II	SCC244	Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer	Recruiting	USA	2
NCT04467723	Phase Ib/II	Atezolizumab + Pirfenidone	Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC	Recruiting	USA	0
NCT04486833	Phase Ib/II	Osimertinib + Quaratusugene Ozeplasmid Carboplatin Cisplatin	Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1)	Recruiting	USA	0
NCT04561362	Phase Ib/II	BT8009 BT8009 + Pembrolizumab	Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| CAN	0
NCT04585477	Phase II	Durvalumab	Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)	Recruiting	USA	0
NCT04603807	Phase III	Entrectinib Crizotinib	A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases	Recruiting	TUR \| SWE \| SVK \| ROU \| NLD \| LBN \| ITA \| HRV \| GRC \| FRA \| ESP \| DEU \| BRA	6
NCT04683250	Phase Ib/II	Vepafestinib	Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities (MARGARET)	Recruiting	USA	1
NCT04693468	Phase I	Axitinib + Talazoparib Crizotinib + Talazoparib Palbociclib + Talazoparib	Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial	Recruiting	USA	0
NCT04884282	Phase II	Docetaxel + OSE 2101 Docetaxel Nivolumab + OSE 2101	Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) (COMBI-TED)	Recruiting	ITA \| FRA \| ESP	0
NCT04892953	Phase II	Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Carboplatin + Durvalumab + Gemcitabine Durvalumab	Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy	Recruiting	USA	0
NCT04929041	Phase II	Ipilimumab + Nivolumab	Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative	Recruiting	USA	0
NCT04940637	Phase II	Dostarlimab-gxly + Niraparib	UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (UNITO-001)	Recruiting	ITA	0
NCT04995523	Phase Ib/II	AZD2936	A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)	Recruiting	USA \| NLD \| GBR \| FRA \| ESP \| DNK \| BRA \| BEL \| AUS	9
NCT05006794	Phase I	GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716	Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies	Recruiting	USA \| ISR	0
NCT05048797	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan	A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations	Recruiting	USA \| TUR \| POL \| NLD \| ITA \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BEL \| AUT	7
NCT05064280	Phase II	Lenvatinib Pembrolizumab	Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases	Recruiting	USA	0
NCT05118789	Phase Ib/II	NUV-520	A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)	Recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	4
NCT05215340	Phase III	Pembrolizumab Datopotamab deruxtecan + Pembrolizumab	Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)	Recruiting	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	9
NCT05255302	Phase II	Pembrolizumab + Pemetrexed Disodium Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab	De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (DIAL)	Recruiting	FRA	0
NCT05311709	Phase II	Sotorasib	Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities (SOLUCOM)	Recruiting	NOR	0
NCT05358548	Phase II	Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab	ATATcH Alternating Treatment Plans for Advanced Cancer	Recruiting	USA	0
NCT05398094	Phase II	Sotorasib	Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy (MERIT-lung)	Recruiting	ESP	0
NCT05401786	Phase II	Cemiplimab Ipilimumab	Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO)	Recruiting	NLD	0
NCT05501665	Phase Ib/II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Pembrolizumab	Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer	Recruiting	USA	0
NCT05541822	Phase II	ABN401 + Lazertinib ABN401	To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation	Recruiting	USA	2
NCT05555732	Phase III	Datopotamab deruxtecan + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Datopotamab deruxtecan + Pembrolizumab Cisplatin + Datopotamab deruxtecan + Pembrolizumab	Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)	Recruiting	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	9
NCT05570825	Phase II	Pembrolizumab + SX-682	SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT05589818	Phase II	Pembrolizumab	Pembrolizumab for Advanced NSCLC and PS 2-3	Recruiting	USA	0
NCT05598853	Phase I	Ipilimumab + Nivolumab	Intrathecal Double Checkpoint Inhibition (IT-IO)	Recruiting	CHE	0
NCT05650879	Phase I	ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002	ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2)	Recruiting	USA \| ITA \| FRA \| ESP \| AUS	2
NCT05676749	Phase I	Aldesleukin + C-TIL051 + Pembrolizumab	C-TIL051 in Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT05681780	Phase Ib/II	Cyclophosphamide + Fludarabine Aldesleukin Nivolumab CD40L-augmented TILs	Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC	Recruiting	USA	0
NCT05715229	Phase II	Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Ipilimumab + Nivolumab	Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (G360-IIT)	Recruiting	USA	0
NCT05769075	Phase I	TY-2136b	A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations	Recruiting	USA	0
NCT05785767	Phase II	Cemiplimab Cemiplimab + Fianlimab	A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)	Recruiting	USA \| TUR \| ISR \| ESP \| CAN \| AUS	5
NCT05788926	Phase I	TG6050	A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)	Recruiting	FRA	0
NCT05815173	Phase I	Ladarixin + Sotorasib	Ladarixin With Sotorasib in Advanced NSCLC	Recruiting	USA	0
NCT05899608	Phase III	Pembrolizumab Ivonescimab	Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients	Recruiting	USA \| POL \| ITA \| IRL \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN	4
NCT05937906	Phase Ib/II	Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Mirdametinib + Pembrolizumab + Pemetrexed Disodium	Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. (IMMUNOMEK)	Recruiting	FRA	0
NCT05984277	Phase III	Carboplatin + MEDI5752 + Pemetrexed Disodium Carboplatin + MEDI5752 + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab	A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02)	Recruiting	USA \| TUR \| SVK \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	8
NCT06031688	Phase II	Tepotinib Ramucirumab + Tepotinib	Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)	Recruiting	USA	0
NCT06074588	Phase III	Docetaxel SKB264 Pemetrexed Disodium	Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)	Recruiting	USA \| TUR \| POL \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| AUS	11
NCT06088771	Phase Ib/II	Cemiplimab + Dupilumab	Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC	Recruiting	USA	0
NCT06116682	Phase II	Amivantamab-vmjw	Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)	Recruiting	USA	0
NCT06116786	Phase I	Cetrelimab + JNJ-86974680	A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer	Recruiting	USA \| ESP \| DEU	1
NCT06119581	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium	A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)	Recruiting	USA \| TUR \| SWE \| ROU \| POL \| NOR \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS	7
NCT06120075	Phase I	AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab	A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27)	Recruiting	USA	0
NCT06140836	Phase III	Repotrectinib Crizotinib	A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)	Recruiting	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| AUT \| ARG	6
NCT06162572	Phase Ib/II	Cemiplimab + S095029 Cemiplimab + Sym024 Cemiplimab + Sym023 Cemiplimab	Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)	Recruiting	USA \| ROU \| ITA \| HUN \| GBR \| FRA \| ESP \| BRA \| BEL \| AUT \| AUS \| ARG	3
NCT06173505	Phase Ib/II	Carboplatin + Pemetrexed Disodium + XmAb20717 Carboplatin + Pembrolizumab + Pemetrexed Disodium	Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC	Recruiting	USA \| POL \| NLD \| GRC \| ESP \| BEL	3
NCT06315010	Phase II	Repotrectinib	REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis (REPOSE)	Recruiting	ESP \| AUT	0
NCT06357533	Phase III	Pembrolizumab AZD2936 + Datopotamab deruxtecan AZD2936	Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC >= 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)	Recruiting	USA \| TUR \| POL \| ITA \| HUN \| GBR \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS	7
NCT06472245	Phase III	OSE 2101 Docetaxel	Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA)	Recruiting	USA \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL	1
NCT06552234	Phase II	Repotrectinib	Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC (REPOROS)	Recruiting	FRA	0
NCT06561386	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium + Relatlimab	A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (RELATIVITY1093)	Recruiting	USA \| TUR \| ROU \| POL \| NZL \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	11
NCT06593522	Phase II	AMG193	A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)	Recruiting	USA \| NLD \| CAN \| BRA \| AUS	7
NCT06627647	Phase III	AZD2936 + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium AZD2936 + Cisplatin + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium	A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC	Recruiting	USA \| TUR \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG	10
NCT06635824	Phase III	Docetaxel GEN1046 + Pembrolizumab	Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)	Recruiting	USA \| NLD \| GBR \| FRA \| BGR	3
NCT06644768	Phase Ib/II	Pembrolizumab DS-3201b + Pembrolizumab	A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations	Recruiting	USA \| BRA \| ARG	3
NCT06726265	Phase III	Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Eftilagimod alpha + Paclitaxel + Pembrolizumab Cisplatin + Eftilagimod alpha + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Eftilagimod alpha + Pembrolizumab + Pemetrexed Disodium	Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)	Recruiting	ROU \| POL \| LVA \| ESP \| BGR \| BEL \| AUS	1
NCT06731907	Phase II	Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Patritumab deruxtecan + Pembrolizumab	A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)	Recruiting	USA \| POL \| ISR \| GRC \| ESP	1
NCT06745882	Phase II	Nab-paclitaxel Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Paclitaxel	Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC	Recruiting	USA	0
NCT06745908	Phase III	Docetaxel Docetaxel + Nogapendekin alfa inbakicept + Tislelizumab	ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT06840782		Cemiplimab Pembrolizumab Durvalumab + Tremelimumab Ipilimumab + Nivolumab Atezolizumab	First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients. (OliGRAIL)	Recruiting	FRA	0
NCT06868277	Phase III	Pembrolizumab AZD2936	A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDELung04)	Recruiting	USA \| TUR \| ROU \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DEU \| BRA \| BGR \| BEL \| AUS \| ARG	6
NCT06918132	Phase II	Cemiplimab + Fianlimab	Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer (N-PLANC)	Recruiting	USA	0
NCT02554812	Phase Ib/II	Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab	A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)	Terminated	USA \| POL \| GBR \| FRA \| CAN \| AUS	2
NCT03064854	Phase I	Canakinumab + Cisplatin + Pemetrexed Disodium + Spartalizumab Canakinumab + Carboplatin + Spartalizumab Carboplatin + Paclitaxel + Spartalizumab Cisplatin + Pemetrexed Disodium + Spartalizumab Cisplatin + Gemcitabine + Spartalizumab	PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients	Terminated	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CZE \| CAN \| BEL	3
NCT03087448	Phase Ib/II	Ceritinib + Trametinib	Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	Terminated	USA	0
NCT03166631	Phase I	BI 891065 + Ezabenlimab BI 891065	A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread	Terminated	USA	0
NCT03317496	Phase II	Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium	Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies	Terminated	USA \| ITA \| HUN \| GBR \| ESP \| CZE \| CAN \| AUS	0
NCT03348904	Phase III	Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Epacadostat + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium	Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer	Terminated	USA	0
NCT03425006	Phase II	Itacitinib + Pembrolizumab	Pembrolizumab and Itacitinib (INCB039110) for NSCLC	Terminated	USA	0
NCT03472560	Phase II	Avelumab + Axitinib	A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)	Terminated	USA \| POL \| ITA \| HUN \| ESP	3
NCT03696212	Phase Ib/II	Grapiprant + Pembrolizumab	Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma	Terminated	USA	0
NCT03827850	Phase II	Erdafitinib	FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)	Terminated	DEU	0
NCT03840902	Phase II	Carboplatin + Paclitaxel Bintrafusp alfa Cisplatin + Etoposide Durvalumab Bintrafusp alfa + Cisplatin + Etoposide Bintrafusp alfa + Carboplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium	M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)	Terminated	USA \| NLD \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG	4
NCT03904108	Phase II	Ramucirumab	Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy	Terminated	USA	0
NCT03996473	Phase Ib/II	Pembrolizumab Pembrolizumab + Radium Ra 223 dichloride	Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases	Terminated	USA \| NLD \| ESP \| BEL	0
NCT04005144	Phase I	Binimetinib + Brigatinib	Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer	Terminated	USA	0
NCT04265534	Phase II	Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium	KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)	Terminated	USA	0
NCT04512430	Phase II	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium	Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients	Terminated	ESP	0
NCT04585815	Phase Ib/II	Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591	Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)	Terminated	USA \| GBR \| BEL \| AUS	1
NCT04800822	Phase I	PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892	PF-07284892 in Participants With Advanced Solid Tumors	Terminated	USA	0
NCT04827576	Phase II	Docetaxel + Hu5F9-G4	Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC)	Terminated	USA \| POL \| GBR \| FRA \| ESP	0
NCT04862780	Phase Ib/II	BLU-945 BLU-945 + Osimertinib	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	Terminated	USA \| NLD \| GBR \| FRA \| ESP \| CAN	4
NCT04863248	Phase II	Docetaxel + Trilaciclib Docetaxel	Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)	Terminated	USA	0
NCT04866017	Phase III	Durvalumab BGBA1217 + Tislelizumab Tislelizumab	A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer	Terminated	USA \| ESP \| AUS	2
NCT04921358	Phase III	Docetaxel Sitravatinib + Tislelizumab	Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Terminated	AUS	1
NCT05241873	Phase Ib/II	BLU-451	(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	Terminated	USA \| CAN	3
NCT05313009	Phase Ib/II	Sotorasib + TH-4000	Tarlox and Sotorasib in Patients With KRAS G12C Mutations	Terminated	USA	0
NCT05469178	Phase Ib/II	Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium	A Clinical Study of Bemcentinib with Standard of Care Chemoimmunotherapy in Untreated Advanced/metastatic Non-small Cell Lung Cancer Patients with a Mutation in the STK11 Gene	Terminated	USA \| POL \| ITA \| HUN \| GRC \| FRA \| ESP	0
NCT05631574	Phase I	BMF-219	Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer	Terminated	USA	1
NCT05709821	Phase Ib/II	Pembrolizumab IMM60 IMM60 + Pembrolizumab	IMM60 and Pembrolizumab in Melanoma and NSCLC	Terminated	USA \| GBR \| ESP	0
NCT05757492	Phase Ib/II	CHS-006 + Toripalimab-tpzi	Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors	Terminated	USA	0
NCT06094296	Phase II	Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel	A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Terminated	USA \| AUS	0
NCT02927340	Phase II	Lorlatinib	A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions	Unknown status	USA	0
NCT03709147	Phase II	Carboplatin + Metformin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Metformin + Pembrolizumab + Pemetrexed Disodium	Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma (FAME)	Unknown status	ITA	0
NCT03896074	Phase II	Atezolizumab + Bevacizumab Atezolizumab	Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT)	Unknown status	ITA	0
NCT03975114	Phase II	Durvalumab + Tremelimumab Durvalumab	A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5)	Unknown status	ITA	0
NCT04250246	Phase II	Ipilimumab + Nivolumab Guadecitabine + Ipilimumab + Nivolumab	A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1)	Unknown status	ITA	0
NCT04292119	Phase Ib/II	Binimetinib + Lorlatinib Crizotinib + Lorlatinib	Lorlatinib Combinations in Lung Cancer	Unknown status	USA	0
NCT04811001	Phase II	Dacomitinib Osimertinib	Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND)	Unknown status	ITA	0
NCT05568212	Phase II	Durvalumab Durvalumab + Olaparib	Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab	Unknown status	ITA	0
NCT03417037	Phase III	Linrodostat + Nivolumab	An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer	Withdrawn	USA \| TUR \| ITA \| GRC \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| AUT \| AUS	4
NCT04151563	Phase Ib/II	Lucitanib + Nivolumab Docetaxel Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Docetaxel + Nivolumab Docetaxel + Nivolumab + Ramucirumab	A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy	Withdrawn	USA \| ROU \| POL \| NOR \| NLD \| GRC \| DNK \| BEL \| ARG	1
NCT04625699	Phase II	Durvalumab + Tremelimumab	Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment	Withdrawn		0
NCT05007769	Phase II	Atezolizumab + Nogapendekin alfa inbakicept + Ramucirumab	Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)	Withdrawn		0
NCT05212922	Phase II	Toripalimab-tpzi + YH001	A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001)	Withdrawn	AUT \| AUS	3
NCT05703555	Phase II	SAR408701	INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 (INTRUSION)	Withdrawn	NLD	0
NCT05815186	Phase II	Ladarixin + Sotorasib	Ladarixin With Sotorasib in Advanced NSCLC - Phase II	Withdrawn	USA	0
NCT05840770	Phase II	Cemiplimab	Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer	Withdrawn		0
NCT05935774	Phase II	Atezolizumab + Trabedersen	OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer	Withdrawn	USA	0

Showing 1 to 186 of 186 entries

Filter rows:

Profile Name	ROS1 rearrange
Gene Variant Detail	ROS1 rearrange (unknown)
Relevant Treatment Approaches	ROS1 Inhibitor

Molecular Profile Detail

Contact

Filtering

Sorting